<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04609930</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0583</org_study_id>
    <nct_id>NCT04609930</nct_id>
  </id_info>
  <brief_title>Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation</brief_title>
  <acronym>ImmunEO</acronym>
  <official_title>Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the impact of anti-checkpoint&#xD;
      immunotherapy on type 2 inflammation via a retrospective analysis of % eosinophilia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in % eosinophilia after initiation of anti-PD-1 and/or anti-PD-L1</measure>
    <time_frame>Before treatment (before day 0) versus after (15 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in % eosinophilia after initiation of anti-PD-1 and/or anti-PD-L1</measure>
    <time_frame>Before treatment (before day 0) versus after (1 month)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in % eosinophilia after initiation of anti-PD-1 and/or anti-PD-L1</measure>
    <time_frame>Before treatment (before day 0) versus after (3 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in % eosinophilia after initiation of anti-PD-1 and/or anti-PD-L1</measure>
    <time_frame>Before treatment (before day 0) versus after (6 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in % eosinophilia after initiation of anti-PD-1 and/or anti-PD-L1</measure>
    <time_frame>Before treatment (before day 0) versus after (12 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Indication leading to anti-PD-1 and/or anti-PD-L1 immunotherapies</measure>
    <time_frame>Day 0</time_frame>
    <description>Name of pathology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age (years)</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sex (male/female)</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies</condition>
  <arm_group>
    <arm_group_label>The study population</arm_group_label>
    <description>Patients in the University Hospitals of Montpellier system who have received anti-PD-1 and/or anti-PD-L1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-PD-1 or anti-PD-L1</intervention_name>
    <description>Immunotherapy treatment via anti programmed death 1 and/or anti-programmed death ligand 1.</description>
    <arm_group_label>The study population</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population corresponds to all patients within the University Hospitals of&#xD;
        Montpellier system who received anti-PDF-1 and/or anti-PD-L1 immunotherapies.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Electronic patient file &quot;DxCare&quot; at the University Hospitals of Montpellier&#xD;
&#xD;
          -  Patient has received anti-PD-1 immunotherapy --AND/OR -- anti-PD-L1 immunotherapy&#xD;
             according to central pharmacy records&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No mention of % eosinophilia in the patient file&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Charriot, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeremy Charriot, MD</last_name>
    <phone>+33 (0)467042020</phone>
    <email>j-charriot@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>UH Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Charriot, MD</last_name>
      <phone>(0)467042020</phone>
      <phone_ext>33</phone_ext>
      <email>j-charriot@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>October 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

